Phathom Pharmaceuticals

Phathom Pharmaceuticals submitted a Citizen Petition to the FDA requesting correction of VOQUEZNA (vonoprazan) tablets' Orange Book listings to reflect a 10-year NCE exclusivity period until May 3, 2032, based on the GAIN Act.

Phathom Pharmaceuticals submitted a Citizen Petition to the FDA requesting correction of Orange Book listings for VOQUEZNA tablets to ensure a 10-year New Chemical Entity exclusivity until May 3, 2032, aligning with VOQUEZNA TRIPLE PAK and DUAL PAK. The exclusivity includes a five-year standard period plus five additional years under the GAIN Act, preventing generic competition. The FDA must respond within 180 days.

BioTech Breakthrough announces 4th annual awards recognizing top life sciences and biotechnology innovations, with winners including Leyden Labs, Rocket Pharmaceuticals, Phathom Pharmaceuticals, and more.

BioTech Breakthrough announced winners of its 4th annual awards, recognizing top biotech companies and innovations in areas like BioPharma, Genomics, Therapeutics, and AI. The program attracted thousands of nominations from 14 countries, highlighting advancements in biological sciences and AI, such as CRISPR and precision medicine.

Phathom Pharmaceuticals to present VOQUEZNA data at ACG 2024, including results from PHALCON-NERD-201 trial on On-Demand dosing for Non-Erosive GERD and nocturnal GERD symptoms.

Phathom Pharmaceuticals to present VOQUEZNA data at ACG 2024, including on-demand treatment for Non-Erosive GERD and nocturnal GERD symptoms, highlighting VOQUEZNA's efficacy and safety.

Biotech and healthcare investment analysis integrating clinical expertise with business strategy, using risk-return charts and DCF analyses. Advocates a barbell portfolio strategy (90% secure assets, 10% high-alpha stocks) within a context of strategic risk management. Influenced by 'Superforecasting' and 'Antifragile' principles, focusing on probabilistic forecasting and robust strategies. No stock positions or plans to initiate within 72 hours. Not personalized investment advice; readers should conduct independent research.